



Ymddiriedolaeth GIG
Prifysgol Felindre
Velindre University
NHS Trust



Pencadlys Ymddiriedolaeth GIG Prifysgol Felindre
Velindre University NHS Trust Headquarters
2 Cwrt Charnwood
Heol Billingsley
Parc Nantgarw
Caerdydd/Cardiff
CF15 7QZ
Ffôn/Phone : (029) 20196161
<https://velindre.nhs.wales>

Date: 28th October 2024
Ref: CORP 2024 - 190

Dear xxx

Freedom of Information request: Melanoma Treatments (CORP 2024 – 190)


Thank you for your request for information which the Trust received on 7th October 2024.

Your Request:

- 1) *How many patients have been treated in the past 3 months with the following agents for melanoma (any stage) :*
 - a. *Cobimetinib*
 - b. *Dabrafenib*
 - c. *Dabrafenib + Trametinib*
 - d. *Dacarbazine*
 - e. *Denosumab*
 - f. *Encorafenib + Binimetinib*
 - g. *Ipilimumab monotherapy*
 - h. *Ipilimumab + Nivolumab*
 - i. *Nivolumab monotherapy*
 - j. *Nivolumab + Relatlimab*
 - k. *Pembrolizumab*
 - l. *Trametinib*
 - m. *Vemurafenib*
 - n. *Vemurafenib + Cobimetinib*
 - o. *Other active systemic anti-cancer therapy*
 - p. *Palliative care only*

- 2) *If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY:*
 - a. *Ipilimumab monotherapy*
 - b. *Ipilimumab + Nivolumab*
 - c. *Nivolumab monotherapy*
 - d. *Nivolumab + Relatlimab*
 - e. *Pembrolizumab*
 - f. *Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)*
 - g. *Other active systemic anti-cancer therapy*
 - h. *Palliative care only*

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.



- 3) *In the last 3 months, how many patients have been initiated* on the following agents for treatment for melanoma?*
- Ipilimumab (monotherapy)*
 - Nivolumab (monotherapy)*
 - Nivolumab AND Ipilimumab (combination)*
 - Nivolumab AND Relatlimab*
 - Pembrolizumab*
 - Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)*
 - Other active systemic anti-cancer therapy*

Please find the Trust's response below:

- 1) **How many patients have been treated in the past 3 months with the following agents for melanoma (any stage) :**
- Cobimetinib**
 - Dabrafenib**
 - Dabrafenib + Trametinib**
 - Dacarbazine**
 - Denosumab**
 - Encorafenib + Binimetinib**
 - Ipilimumab monotherapy**
 - Ipilimumab + Nivolumab**
 - Nivolumab monotherapy**
 - Nivolumab + Relatlimab**
 - Pembrolizumab**
 - Trametinib**
 - Vemurafenib**
 - Vemurafenib + Cobimetinib**
 - Other active systemic anti-cancer therapy**
 - Palliative care only**

There have been 172 patients treated for Melanoma with the above. This is the number of unique patients treated, some may have received more than of these drugs/treatments.

- 2) **If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY:**
- Ipilimumab monotherapy**
 - Ipilimumab + Nivolumab**
 - Nivolumab monotherapy**

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.

- d. Nivolumab + Relatlimab
- e. Pembrolizumab
- f. Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
- g. Other active systemic anti-cancer therapy
- h. Palliative care only

The Trust does not record the data requested in a format that enables the information to be easily retrieved to the level of detail required to specifically answer your request.

In reaching this decision we estimate that it would take a minimum of 22 hours or £550 an amount of £100 over the core amount of £450 extra to obtain the data. The amount would require payment in full prior to the Trust undertaking the work. This is due to requiring a manual review of free text fields and patient notes to determine the numbers.

As result, the Trust is applying an exemption under Section 12 Freedom of Information Act (Exemption where cost of compliance exceeds appropriate limit), the legislation in this instance states:

12 Exemption where cost of compliance exceeds appropriate limit.

- (1) Section 1(1) does not oblige a public authority to comply with a request for information if the authority estimates that the cost of complying with the request would exceed the appropriate limit.

The Trust has a duty to advise and assist you under Section 16 of the Act and therefore may I suggest that you consider the option to revise your request so that it falls below the prescribed appropriate limit.

- 3) In the last 3 months, how many patients have been initiated* on the following agents for treatment for melanoma?
- a. Ipilimumab (monotherapy)
 - b. Nivolumab (monotherapy)
 - c. Nivolumab AND Ipilimumab (combination)
 - d. Nivolumab AND Relatlimab
 - e. Pembrolizumab
 - f. Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
 - g. Other active systemic anti-cancer therapy

There have been 62 patients initiated on the above. This is the number of unique patients treated, some may have received more than of these drugs/treatments.

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg. Velindre University NHS Trust is happy to receive communication in Welsh or English.



Ymddiriedolaeth GIG
Prifysgol Felindre
Velindre University
NHS Trust



Pencadlys Ymddiriedolaeth GIG Prifysgol Felindre
Velindre University NHS Trust Headquarters
2 Cwrt Charnwood
Heol Billingsley
Parc Nantgarw
Caerdydd/Cardiff
CF15 7QZ
Ffôn/Phone : (029) 20196161
<https://velindre.nhs.wales>

I trust this answers your request for information, however, should you not be satisfied with the information supplied or the process of supplying it, you have a right to complain and request a review. Please note that you must submit a request for a review within 40 days of the date of this letter.

You should forward your complaint to:

Mr Ian Bevan via FOI.VUNHST@wales.nhs.uk
Head of Information Governance
Velindre University NHS Trust
2, Charnwood Court
Heol Billingsley
Parc Nantgarw
Cardiff / Caerdydd
CF15 7QZ

Should you wish to take your complaint further, if you are still unhappy with the decision after review, you can contact the:

Information Commissioner's Office - Wales
2nd Floor,
Churchill House,
Churchill Way,
Cardiff,
CF10 2HH
Telephone: 0330 414 6421
email: wales@ico.org.uk

Yours sincerely

Non Gwilym
Interim Director of Corporate Governance
Velindre University NHS Trust
2 Charnwood Court
Heol Billingsley
Parc Nantgarw
Cardiff
CF15 7QZ

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.

